BIOVIIIx is a biotech & pharmaceutical company operating in the field of hemocoagulopathies and rare diseases, with particular specialization in the hemophilia segment. Thanks to the expertise of our management and all our resources, we are able to carry forward a model that combines scientific research with a market approach that stands out for the enormous consideration we reserve for ethical principles and respect. Furthermore, in order to introduce innovative methodologies and tools that improve patient support and with a view to upgrading internal and external business flows, we have chosen to start scientific research initiatives in collaboration with universities, organizations and specialized national and international centers. . A process that starts from the identification of the financing initiatives that are functional to the development of the activity and the best resources available for the success of the same. For these purposes, the BIOVIIIx group is part of today: - AnBition Start Up controlled by BIOVIIIx in collaboration with CNR -IGB - Naples, Italy Startup based in Naples, deals with innovative biotechnological research in the Antitumor field more specifically the projects on which is focused on the inhibition of angiogenesis, the newborn Start Up has filed international patents in this regard and is strongly committed to the development of new pharmaceutical forms and new routes of administration of the developed therapies. - 3P Sense LTD - London Startup based in London, deals with innovative biotechnological research and in 2016 obtained the patent "Cantilever sensors for molecule detection". - Oncovix Startup specialized in cancer research, in 2017 obtained the patent for a new cancer drug "Duo Fix Combination" for pancreatic cancer. #BIOVIIIx
Company Details
- Employees
- 39
- Founded
- -
- Address
- Via Alessandro Manzoni, 1, Napoli,na 80123,italy
- Phone
- +39.081.239.5462
- in****@****iix.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- bioviiix.com
- Keywords
- Haemophilia, Market Biological Access, Haemostasis, Critical Care, market Access, Trasfusional, rare disease, willebrand, coagulation, oncology, Hematology, Immunology, critical care, monoclonal, diagnostic, thrombosis, rare disease, orphan drug, proteins, coagulation factors, thrombin generatiom, thrombin generation, Blood, Biotech, Research, hemophilia, science, pharma, medical, pharmaceutical, drugs, salute, sanità, health, company, reseller, rare diseases, haemophilia awareness, pathology, pathologies, innovation, cancer cure, hospital, laboratory, plasma.
- HQ
- Napoli, Na
Bioviiix Questions
Bioviiix's helpline number is +39.081.239.5462
Bioviiix's website is bioviiix.com
Bioviiix's LinkedIn profile is https://it.linkedin.com/company/bioviiix
Bioviiix has
39 employees.
View email and phone details for 39
employees at Bioviiix.
Bioviiix's industry is
Biotechnology Research
Bioviiix's top competitors are
It Health Fusion,
Negedia,
Reithera,
Arterra Bioscience S.p.a.,
Farmaceutici Damor S.p.a.,
Biogem Istituto Di Biologia E Genetica Molecolare,
Cluster Campania Bioscience,
Genetic Spa,
Microbiolife,
Kedrion Biopharma.
Bioviiix's support email address is info@bioviiix.com
Bioviiix's categories are Biotechnology Research
Bioviiix's founding year is 2013
